GHO Capital invests in CDMO RoslinCT cell therapy

Global healthcare opportunities, or GHO Capital Partners LLP, a specialist European investor, has invested in RoslinCT, a contract development and manufacturing organization ( CDMO ) focused on advanced cell therapies.

Founded in 2006 in Edinburgh, Scotland, with support from Scottish Enterprise, RoslinCT was established through an initial spin-off from the Roslin Institute, which has a proven track record in genetic and cellular biology.

Since 2014, the company has had a manufacturing base within the Center for Regenerative Medicine at the University of Edinburgh in a facility shared with the Scottish National Blood Transfusion Service. RoslinCT has worked to advance the field of regenerative medicine and today is at the forefront of high quality cell therapy development and manufacturing. The company recently expanded into the facilities of the Edinburgh BioQuarter and is recognized worldwide as a unique CDMO establishing its own production on a commercial scale.

RoslinCT serves an established international customer base of leading pharmaceutical and biotechnology companies, in partnership from the development phase through to advanced clinical manufacturing. The company is expected to experience exponential growth in the advanced therapy market, which is expected to grow by up to 50% per year.

With the support of GHO, RoslinCT will significantly increase its development and manufacturing capacity, supporting customer acquisition and product diversification.

RoslinCT will benefit from GHO’s industry expertise and international resources to accelerate its growth, evolve the business to build on its best-in-class therapies and better serve a growing international clientele.

GHO Capital partners commented, “RoslinCT is renowned for its world-class services in the development and manufacture of advanced cell therapies and we are delighted to join the team. With an established track record in regenerative medicines and a strong foothold in Scotland as a leading center for cell therapy research, RoslinCT, with our investments and specialist expertise, is uniquely positioned to drive the next stage of its growth. We look forward to realizing RoslinCT’s shared ambition to become a global CDMO with commercialized cell therapy manufacturing capabilities. “

Janet Downie of RoslinCT said: “After building RoslinCT and our highly skilled team over many years, I am delighted to have the support of GHO. GHO has extensive healthcare expertise which is essential as we seek to drive global growth and expand our operations to meet growing international demand. With tremendous advancements in the cell therapy industry, RoslinCT is now perfectly positioned to become a truly global CDMO, having grown in strength in recent years. I see this as a very natural and exciting step for the business and we look forward to taking further steps with the support of GHO.

Malcolm Bateman, CEO of The Roslin Foundation, added: “I am delighted to recognize the success of the company that I, along with my colleagues at the Roslin Institute, established in 2006. The Roslin Foundation has enjoyed working with it. excellent RoslinCT team over the years. This is a fantastic achievement and we are confident that the company, in partnership with GHO, will continue to set the standard for manufacturing high quality cell therapy. We wish everyone involved the best for the future.

Slaughter & May acted as legal advisor to GHO, and Alvarez and Marsal acted as both financial and tax advisor, Deloitte as structuring advisor, ClearView Healthcare Partners as business advisor, Dark Horse Consulting Group as technical advisor and ERM as ESG advisor.

Torreya Partners (Europe) LLP served as financial advisor to RoslinCT and Dentons provided legal advice.

Comments are closed.